Diana Samson

TL;DR: These revised and updated guidelines include new sections on imaging and the management of skeletal disease, cover new developments in disease classification and staging and the use of new therapeutic approaches, such as thalidomide, bortezomib and reduced-intensity allogeneic transplantation.

TL;DR: It is concluded that ASCT is safe and effective and the outcome is independent of age, time from diagnosis, previous treatment and conditioning regimen and the international prognostic index at transplant.

TL;DR: 15 out of 163 patients who underwent SCT and relapsed with plasmacytomas only without evidence of bone marrow disease progression are presented here, with cases of unconventional disease recurrence likely to be seen due to sub‐clinical seeding of tumour cells suggestive of the presence of an extramedullary (EM) clone of plasma cells with a high degree of chemoresistance.

TL;DR: It is concluded that ASCT is a safe and effective procedure even in resistant cases, independent of age, time from diagnosis, previous treatment and conditioning regimen, but there was a tendency for better survival in the nonsecretory patients.

TL;DR: There was no difference in event‐free survival (EFS) between the CD34+‐selected group and the unselected group (median 21 and 26 months, respectively, P=ns).